4/7/2010

The FDA gave fast-track status to the review of Allon Therapeutics' davunetide. The drug will undergo Phase II trials for the treatment of progressive supranuclear palsy, a fatal neurodegenerative disease.

Full Story:
CBC.ca (Canada)

Related Summaries